Immunis, Inc., a clinical-stage biotech developing novel, multi-active biologics for age and disease-related immune dysregulation, is proud to announce the successful completion of its Phase 1/2a ...
According to a 2023 study published in The Lancet Rheumatology, nearly 1 billion people worldwide will be affected by the most common form of arthritis: osteoarthritis. Currently, the condition ...